Merck's Transformation Gains Momentum with Strong Pipeline, Animal Health Performance

Merck CEO Rob Davis sees the company's transformation gaining momentum through positive pipeline readouts, new product launches, business development, and strong Animal Health performance. The company's goal of generating more than $70 billion in revenue from recent launches and pipeline products by the mid-2030s may have upside, citing opportunities such as individualized neoantigen therapy and Terns. Davis also emphasized the need for reforms in pharmacy benefit managers and the federal drug-pricing program to address issues with drug affordability and patient access.